Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (4979)	7/24/1998 11:29:00 AM
From: Izzy	Read Replies (2) of 6136

Henry, enjoyed reading the WSJ MRK article and the favorable information on the continued success of Viracept. However, it fails to mention how MRK is going to solve the problem of Crixivan causing serious kidney stones in up to 10% of patients (forget the TID [3X/day] dosage; that's not the major problem with Crix) and the drug resistance issue. I personally take affront to Dr. Saag's comment: "He adds that he generally reserves use of protease inhibitors until patients have failed other drug therapies. Every regimen will fail ultimately." IMO, what a terrible clinical philosophy and it certainly can't be that reassuring to HIV patients. Wonder if he says the same thing to cancer patients receiving chemotherapy. Just my 1st impressions after quickly reading the long article. BTW, do you think that MRK will buyout LGND? Looks like it needs a good drug pipeline.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next